<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27412146</article-id><article-id pub-id-type="pmc">4970666</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2015708594</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000002918</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>20</subject><subject>302</subject><subject>100</subject><subject>101</subject><subject>322</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Chronic migraine headache prevention with noninvasive vagus nerve stimulation</article-title><subtitle>The EVENT study</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Silberstein</surname><given-names>Stephen D.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Alder, (2) Allergan, (3) Amgen, (3) Avanir,(4)eNeura, (5) ElectroCore Medical, (6) Medscape, (7) Medtronic, (8) Mitsubishi Tanabe, (9) Neuralieve, (10) NINDS, (11) Pfizer, (12) Supernus, (13) Teva, (14) Curelator, (15) Depomed, (16) Dr. Reddy's Laboratories, (17) Lilly, (18) Trigemina</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Cephalalgia, (2) Current Pain and Headache Reports, (3) CNS Drugs, (4) Topics in Pain Management, (5) Neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Allergan, (2) Amgen, (3)eNeura, (4) ElectroCore Medical, (5) Mitsubishi Tanabe, (6) Medtronic, (7) Neuralieve, (8) Pfizer, (9) Supernus, (10) Teva</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>None now; past 2 years: (1) Allergan, (2) Endo Pharmaceuticals, (3)GlaxoSmithKline, (4) Zogenix, (5) Merck</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Past 2 years: (1) GlaxoSmithKline, (2) Allergan, (3) Merck, (4) Novartis, (5) NIH, (6) Neurolieve, (7) MAP, (8) Endo Now: Amgen, ElectroCore, Avanir</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) NIH</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) AHS, (2) IHS</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Calhoun</surname><given-names>Anne H.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Depomed (2) Eli Lilly</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Depomed (2) Merck (3) Teva</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Autonomic Technologies (2) ElectroCore (3) Scion Neurostim</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Lipton</surname><given-names>Richard B.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Allergan, e-Neura, Merck</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Serve as consultant, advisory board member or received honoraria from: Alder, Allergan, American Headache Society, Autonomic Technologies, Avanir, Boehringer- Ingelheim, Boston Scientific, Bristol Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly, eNeura Therapeutics, Informa, Merck, Novartis, Pfizer, Teva, Vedanta</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Oxford University Press; Baxter Publishing</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Serve as consultant, advisory board member or received honoraria from: Alder, Allergan, American Headache Society, Autonomic Technologies, Avanir, Boehringer- Ingelheim, Boston Scientific, Bristol Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly, eNeura Therapeutics, Informa, Merck, Novartis, Pfizer, Teva, Vedanta</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Bristol Myers Squibb Early Detection of Alzheimer's Disease June 2010 - present Vedanta Research Migraine epidemiology and Progression June 2010 - present Boston Scientific Occipital Nerve Stimulation in Migraine March 2013 - present ElectroCore Vagal Nerve Stimulation for Migraine and Cluster May 2013 Novartis Sleep and Migraine September 2012 - present Allergan Botox in Migraine April 2012 - present Allergan Chronic Migraine Epidemiology and Outcome Study January 2012 - present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>P01 AG03949 4/1/11-3/31/16 Einstein Aging Study Role: Principle Investigator 1KL2RR025749 07/01/09-06/30/13 Clinical and Translational Science Award (CTSA) Research Career Development Award Role: Primary Mentor R01AG022374 8/1/10-7/31/15 Biomarkers in Early Alzheimer?s Disease Role: Investigator R01AG034119 8/1/10-7/31/15 Two Preclinical Latent Scores to Predict Occurrence of DAT Role: PI, Einstein Site R01AG012101 9/15/10-7/31/15 MRI Progression Markers of Cognitive Decline in the Elderly Role: PI, Einstein Site 1R01AG039409-01 Stress, Unconstructive Repetitive Thought &#x00026; Cognitive Aging 4/1/11-3/31/16 Role: PI, Einstein Site 1R01AG038651-01A1 Role of impaired cognitive states &#x00026; risk factors in conversion to mixed dementias 9/1/11-8/31/16 Role: PI, Einstein Site 1U10NS077308- 01 9/30/11-8/31/18 Einstein Center for Excellence for Clinical Trials in Neuroscience Role: PI NIH 4/1/12-3/31/17 Behavioral Weight Loss as a Treatment for Migraine in Obese Women Role: Investigator NIH 1R01AG042595 - 01A1 Stress, cognition, repetitive unconstructive thoughts and inflammatory markers Role: Investigator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>S &#x00026; L Marx Foundation Alzheimer's Research</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>eNeura Pharma</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>Oxford University Press; Baxter Publishing</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Grosberg</surname><given-names>Brian M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Pernix</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Wiley</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>Expert testimony for a legal proceeding on behalf of industry</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cady</surname><given-names>Roger K.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Aerocrine, Allergan, Avanir, Autonomic Technologies, Boston Scientific, DepoMed, Dr. Reddy?s Laboratories, ElectroCore, Novartis, Suda, and Teva Pharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Headache, Journal of Headache and Face Pain, Associate Editor, 1 year</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>--Photostimulation Device for Treatment and Prevention of Headaches --Preemptive Prophylaxis of Migraine Device and Method</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>--Managing Migraine, A Healthcare Professional's Guide to Collaborative Migraine Care, by: Richard B. Lipton, MD, Roger K. Cady, MD, Kathleen Farmer, PsyD, and Marcelo E. Bigal, MD, PhD --Managing Migraine, A Patient's Guide to Successful Migraine Care, by: Richard B. Lipton, MD, Roger K. Cady, MD, Kathleen Farmer, PsyD, and Marcelo E. Bigal, MD, PhD --Chronic Migraine, A Patient-Centered Guide to Effective Migraine Care, by: Roger K. Cady, MD, Richard B. Lipton, MD, and John F. Rothrock, MD --The Adherence Principle Empowering Your Healthy Self, by: Roger K. Cady, MD and Kathleen Farmer, PsyD</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Banyan Group, Inc., CEO</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Aerocrine, Amgen, Avanir, Becker Pharma, DepoMed, Dr. Reddy?s Laboratories, Inc., Impax Pharmaceuticals, Suda, Teva Pharmaceuticals, and Zosano.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Allergan, DepoMed, Impax Pharmaceuticals, and Teva Pharmaceuticals.</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Alder Pharmaceuticals, Allergan, Amgen, AstraZeneca, Autonomic Technologies, Avanir, Boston Scientific, Capnia, Daiichi- Sankyo, Dr. Reddy?s Laboratories, ElectroCore, Eli Lily, EPI- Q, inc., ISIS Pharmaceuticals, Labrys Biologics, Pharmalyte Solutions LLC, Questcor, Tian Medical, and Vivid Pharma Inc.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>See book royalties</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dorlas</surname><given-names>Stefanie</given-names></name><degrees>BMath, BEd</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>MedLogix Communications, LLC, Medical Writer, 8 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Non-financial disclosures:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Simmons</surname><given-names>Kristy A.</given-names></name><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>electroCore llc, Study Manager, 2010-2015</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>electroCore llc Stock/Stock Options, Medical Equipment &#x00026; Materials: electroCore llc.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>electroCore llc.</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Mullin</surname><given-names>Chris</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Cardiovascular Translational Research, Editorial Board, 2012-current</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NAMSA, Director Product Development Strategy, 12 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Liebler</surname><given-names>Eric J.</given-names></name><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) electroCore, LLC, VP: Scientific, Clinical and Medical Affairs, 4 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) electroCore, llc. Stock/Stock Options, Medical Equipment &#x00026; Materials: electroCore, llc., 2013-2016</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>electroCore, llc., 2013-2016</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Goadsby</surname><given-names>Peter J.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Dr. Goadsby reports personal fees from Ajinomoto Pharmaceuticals Co, Akita Biomedical, Alder Biopharmaceuticals, grants and personal fees from Allergan, grants and personal fees from Amgen, personal fees from Avanir Pharma, personal fees from Cipla Ltd, Colucid Pharmaceuticals, Ltd, Dr Reddy's Laboratories, grants and personal fees from Eli-Lilly and Company, personal fees from Electrocore LLC, grants and personal fees from eNeura Inc, personal fees from Ethicon , US, WL Gore &#x00026; Associates, Heptares Therapeutics, Nupathe Inc, Pfizer Inc, Promius Pharma, Scion, Teva Pharmaceuticals, and Trigemina Inc.,</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Brain- Associate Editor; Neurology - Editorial Board</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Dr. Goadsby has a patent Magnetic stimulation for headache pending</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>As above</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>MedicoLegal work in headache</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Saper</surname><given-names>Joel R.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Alder, Allergan, Eli Lilly, Supernus, Teva, Alder, Tian, Zecuity, Gavis, &#x00026; Migraine Research Foundation.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial Board - Pain Medicine</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Lilly.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Achelios, GlaxoSmithKline, Astellas, Merck, Alder, Allergan, Amgen, Inc., Autonomic Technologies, Inc., Cerephex Corporation, Daiichi Sankyo, Dr. Reddy?s Laboratories Ltd., Eli Lilly, Labrys Biologics, Pfizer, Inc., Scion &#x00026; Tonix.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Migraine Research Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment><on-behalf-of>On behalf of the EVENT Study Group</on-behalf-of></contrib><aff>From Jefferson Headache Center (S.D.S.), Philadelphia, PA; Carolina Headache Institute (A.H.C.), Chapel Hill, NC; Montefiore Headache Center and Albert Einstein College of Medicine (R.B.L.), Bronx, NY; Hartford HealthCare Headache Center (B.M.G.), West Hartford, CT; Clinvest Headache Care Center (R.K.C.), Springfield, MO; MedLogix Communications, LLC (S.D.), Schaumburg, IL; electroCore, LLC (K.A.S., E.J.L.), Basking Ridge, NJ; NAMSA (C.M.), Minneapolis, MN; University of California San Francisco (P.J.G.); King's College London (P.J.G.), UK; and Michigan Headache and Neurological Institute (J.R.S.), Ann Arbor. B.M.G. was affiliated with Montefiore Headache Center, Bronx, NY, at the time of study completion.</aff></contrib-group><contrib-group><contrib contrib-type="collab"><collab>EVENT Study Group</collab></contrib><contrib contrib-type="collab"><name><surname>Calhoun</surname><given-names>Anne H.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Cady</surname><given-names>Roger K.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dexter</surname><given-names>John</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Silberstein</surname><given-names>Stephen D.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Young</surname><given-names>William</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Marmura</surname><given-names>Michael</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Nahas-Geiger</surname><given-names>Stephanie</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Da Silva</surname><given-names>Arnaldo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Saper</surname><given-names>Joel</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Weintraub</surname><given-names>James</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Prestegaard</surname><given-names>Alicia</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sinka</surname><given-names>Erik</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Grosberg</surname><given-names>Brian</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vollbracht</surname><given-names>Sarah</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Issa</surname><given-names>Shirin</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Lipton</surname><given-names>Richard</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mullin</surname><given-names>Kathleen</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pavlovic</surname><given-names>Jelena</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Robbins</surname><given-names>Matthew</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Goadsby</surname><given-names>Peter</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Gelfand</surname><given-names>Amy</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Eller</surname><given-names>Michael</given-names></name><degrees>MD</degrees></contrib></contrib-group><author-notes><corresp>Correspondence to Dr. Silberstein:<email>stephen.silberstein@jefferson.edu</email></corresp><fn fn-type="other"><p>Coinvestigators are listed on the <italic>Neurology</italic>&#x000ae; Web site at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by electroCore, LLC.</p></fn></author-notes><pub-date pub-type="ppub"><day>02</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>02</day><month>8</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>87</volume><issue>5</issue><fpage>529</fpage><lpage>538</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 American Academy of Neurology</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2015708594.pdf"/><abstract><sec><title>Objective:</title><p>To evaluate the feasibility, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS) for the prevention of chronic migraine (CM) attacks.</p></sec><sec><title>Methods:</title><p>In this first prospective, multicenter, double-blind, sham-controlled pilot study of nVNS in CM prophylaxis, adults with CM (&#x02265;15 headache d/mo) entered the baseline phase (1 month) and were subsequently randomized to nVNS or sham treatment (2 months) before receiving open-label nVNS treatment (6 months). The primary endpoints were safety and tolerability. Efficacy endpoints in the <italic>intent-to-treat population</italic> included change in the number of headache days per 28 days and acute medication use.</p></sec><sec><title>Results:</title><p>Fifty-nine participants (mean age, 39.2 years; mean headache frequency, 21.5 d/mo) were enrolled. During the randomized phase, tolerability was similar for nVNS (n = 30) and sham treatment (n = 29). Most adverse events were mild/moderate and transient. Mean changes in the number of headache days were &#x02212;1.4 (nVNS) and &#x02212;0.2 (sham) (&#x00394; = 1.2; <italic>p</italic> = 0.56). Twenty-seven participants completed the open-label phase. For the 15 completers initially assigned to nVNS, the mean change from baseline in headache days after 8 months of treatment was &#x02212;7.9 (95% confidence interval &#x02212;11.9 to &#x02212;3.8; <italic>p</italic> &#x0003c; 0.01).</p></sec><sec><title>Conclusions:</title><p>Therapy with nVNS was well-tolerated with no safety issues. Persistent prophylactic use may reduce the number of headache days in CM; larger sham-controlled studies are needed.</p></sec><sec><title>ClinicalTrials.gov identifier:</title><p>NCT01667250.</p></sec><sec><title>Classification of evidence:</title><p>This study provides Class II evidence that for patients with CM, nVNS is safe, is well-tolerated, and did not significantly change the number of headache days. This pilot study lacked the precision to exclude important safety issues or benefits of nVNS.</p></sec></abstract><funding-group><award-group><funding-source>NIH</funding-source><award-id>PO1AG003949 (program director), RO1AG025119 (investigator), RO1AG022374-06A2 (investigator), RO1AG034119 (investigator), and RO1AG12101 (investigator)</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta><custom-meta><meta-name>cme</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Migraine is a disabling neurologic headache disorder with symptoms including nausea and sensitivity to light/sound.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Compared with episodic migraine (headache occurring &#x0003c;15 d/mo), chronic migraine (CM; headache occurring &#x02265;15 d/mo) leads to greater disability and lower productivity.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Although preventive &#x003b2;-blockers, tricyclic antidepressants, and anticonvulsants are used off-label in CM,<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> onabotulinumtoxinA is the only approved prophylactic CM medication.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup></p><p>Neuromodulation using implanted vagus nerve stimulation (VNS) devices has demonstrated efficacy for the treatment of epilepsy<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and depression<sup><xref rid="R7" ref-type="bibr">7</xref></sup> and potential efficacy for migraine prophylaxis.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> Case reports and small studies of patients who received implanted VNS devices for epilepsy showed reductions in migraine attack frequency and severity.<sup><xref rid="R8" ref-type="bibr">8</xref><xref ref-type="bibr" rid="R9">&#x02013;</xref><xref rid="R12" ref-type="bibr">12</xref></sup> Epilepsy and depression studies of VNS suggest that efficacy improves with time on therapy<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup>; however, this association has not been investigated in migraine prophylaxis.</p><p>Despite the potential benefits of implanted VNS therapy, the high risks and costs of surgical implantation have hindered its clinical evaluation. A patient-controlled, handheld, noninvasive VNS (nVNS) device (gammaCore&#x000ae;; electroCore, LLC, Basking Ridge, NJ) has been CE-marked for the treatment of primary headache disorders (including migraine). Here we describe preliminary experience with nVNS for CM prophylaxis. These data were first reported at the 56th annual meeting of the American Headache Society (June 26&#x02013;29, 2014; Los Angeles, CA).<sup><xref rid="R13" ref-type="bibr">13</xref></sup></p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Primary objective.</title><p>The objective of this study was to assess the feasibility, safety, and tolerability of nVNS; it was not powered to assess efficacy.</p></sec><sec id="s1-2"><title>Standard protocol approvals and patient consents.</title><p>The protocol was approved by site-specific institutional review boards for 2 of the 6 participating sites and by the Biomedical Research Alliance of New York institutional review board for the remaining 4 sites. All participants provided signed informed consent before enrollment.</p></sec><sec id="s1-3"><title>Study design.</title><p>This prospective pilot study of nVNS for CM prophylaxis was conducted at 6 US tertiary care headache centers between October 2012 and April 2014 (EVENT; <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> NCT01667250). The study comprised 3 consecutive phases: a 1-month baseline phase to collect pretreatment data and medical history; a 2-month, double-blind, randomized, sham-controlled phase, during which participants received prophylactic treatment with nVNS or a sham device; and a 6-month open-label phase, during which all participants received nVNS treatment. For the total 8-month treatment period, the end of the 2-month randomized phase was denoted as <italic>month 2</italic>, and the three 2-month evaluation points during the 6-month open-label phase were denoted as <italic>months 4, 6</italic>, and <italic>8</italic>.</p></sec><sec id="s1-4"><title>Study population.</title><p>Participants were aged 18&#x02013;65 years and previously diagnosed with CM with/without aura according to the revised <italic>International Classification of Headache Disorders, second edition</italic>, criteria,<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> had migraine onset before 50 years of age, and had &#x02265;15 headache d/mo during the previous 3 months.</p><p>Key exclusion criteria were a history of aneurysm, intracranial hemorrhage, brain tumor, or head trauma; a lesion, dysesthesia, previous surgery, or abnormal anatomy at the treatment site; known or suspected cardiovascular disease; uncontrolled hypertension; abnormal ECG results; recent myocardial infarction; an implanted electrical/neurostimulator device; a metallic implant/metal cervical spine hardware near the stimulation site; previous surgery for migraine prevention; onabotulinumtoxinA injections for migraine prevention during the previous 6 months; and prophylactic migraine medication during the previous 30 days. Modifications in prophylactic medication type/dose for indications other than CM that could interfere with the study were not permitted.</p></sec><sec id="s1-5"><title>Randomization and blinding.</title><p>An independent statistician generated a randomization schedule to assign participants 1:1 (variable block design stratified by study center) to prophylactic treatment with nVNS or sham treatment. The study sponsor (electroCore, LLC) prelabeled the devices according to each site's randomization scheme; a third-party distributor provided the devices to study sites. An unblinded trainer provided participants with the devices and instructions on device features, proper use, and treatment schedules. Participants, investigators, and study coordinators were blinded to treatment assignment during the randomized phase.</p></sec><sec id="s1-6"><title>Interventions.</title><p>The nVNS device produced a proprietary electrical signal that delivered a low voltage (peak, 24 V) and a maximum output current of 60 mA. Users adjusted the stimulation amplitude within a preset range. Two stainless steel contact surfaces coated with a conductive gel enabled delivery of stimulations to the neck in the vicinity of the vagus nerve (figure e-1 on the <italic>Neurology</italic>&#x000ae; Web site at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link>). The sham device was identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations. Each treatment consisted of two 2-minute self-administered stimulations delivered 5&#x02013;10 minutes apart to the right side of the neck at 3 prespecified times every day: (1) within 1 hour of awakening; (2) 6&#x02013;8 hours after the first treatment; and (3) 6&#x02013;8 hours after the second treatment. Acute headache medication use was permitted throughout the study.</p></sec><sec id="s1-7"><title>Assessments and endpoints.</title><p>Participants used diaries to record safety and tolerability (primary endpoints), efficacy, and satisfaction data. Investigators categorized the onset, type, severity (mild, moderate, severe), and frequency of adverse events (AEs) according to treatment relatedness. Serious AEs (SAEs) were defined by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Guidance for Good Clinical Practice.</p><p>The number of reported headache days per month was normalized to the number of headache days per 28 days, which was the primary efficacy measure. A <italic>headache day</italic> was defined as any day on which a participant recorded a headache. The mean change from baseline in the number of headache days was evaluated at the end of the randomized phase (month 2) and through the end of the open-label phase (at 4, 6, and 8 months of treatment). Post hoc efficacy analyses assessed the effect of treatment duration on the number of headache days and determined the <italic>percent treatment response</italic>, defined as the proportion of participants who demonstrated &#x02265;50% reduction from baseline in the number of headache days.</p><p>The rate of patient-reported acute medication use and treatment adherence, satisfaction, and ease of use were evaluated throughout both phases. Treatment adherence ([actual number of administered treatments]/[total number of scheduled treatments] &#x000d7; 100) was calculated as the average daily adherence. Treatment satisfaction was assessed on a 5-point scale (<italic>extremely satisfied</italic> to <italic>not at all satisfied</italic>). Ease of use was rated on a 4-point scale (<italic>very easy</italic> to <italic>very difficult</italic>). One week into the randomized phase and at its end, study blinding effectiveness questionnaires were completed.</p></sec><sec id="s1-8"><title>Statistical methods.</title><p>No formal sample size calculations were performed; the sample size was selected to facilitate initial assessment of feasibility and tolerability in a clinically relevant number of participants. All analyses were conducted on the <italic>intent-to-treat (ITT) population</italic>, which included all participants who were randomly assigned to treatment and provided data for each outcome. Missing data were imputed using last observation carried forward (LOCF). To assess the effect of protocol deviation and discontinuations, sensitivity analyses were performed on the <italic>per-protocol (PP) population</italic>, which included only participants who completed each phase with no major protocol violations. Pooled participants from both treatment groups in the <italic>PP population</italic> (i.e., the <italic>PP completer population</italic>) were stratified and analyzed by the total duration of nVNS treatment completed throughout the study (2-, 4-, 6-, or 8-month completers). Specifically, 2-month completers comprised participants in the nVNS group who completed the 2-month randomized phase and participants in the sham group (controls) who completed 2 months of open-label nVNS treatment.</p><p>There were no formal a priori statistical analyses; exploratory post hoc analyses were conducted to determine the effect of nVNS treatment duration on the mean change in number of headache days and to compare treatment responses for nVNS and sham. Categorical variables were compared using the Fisher exact test (if &#x02265;1 cell had an expected frequency &#x02264;5) or &#x003c7;<sup>2</sup> analyses. Continuous variables were compared using the Student <italic>t</italic> test and the Wilcoxon rank sum test for normal and non-normal distributions, respectively. Blinding questionnaire results were analyzed using the Bang index<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and corresponding 95% confidence intervals (CIs).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Participants.</title><p>Fifty-nine of the 73 participants in the baseline phase were eligible for randomization and constituted the <italic>ITT population</italic> (nVNS, n = 30; sham, n = 29) (<xref ref-type="fig" rid="F1">figure 1</xref>). A total of 51 participants (nVNS, n = 26; sham, n = 25) from the <italic>ITT population</italic> and 49 participants (nVNS, n = 26; sham, n = 23) from the <italic>PP population</italic> (i.e., no violations) completed the randomized phase, and 48 participants (nVNS, n = 24; sham, n = 24) from the <italic>ITT population</italic> and 47 participants (nVNS, n = 24; sham, n = 23) from the <italic>PP population</italic> continued into the open-label phase. Twenty-seven participants completed the study (nVNS, n = 16; sham, n = 11). Safety analyses were performed on all 59 participants from the <italic>ITT population</italic>. Demographic and baseline characteristics were similar to those reported in other migraine studies (<xref ref-type="table" rid="T1">table 1</xref>).<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Participants (mean age, 39 years; mean headache frequency, &#x0003e;20 d/mo) were predominantly Caucasian women.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Participant disposition</title><p>nVNS = noninvasive vagus nerve stimulation.</p></caption><graphic xlink:href="NEUROLOGY2015708594FF1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participant demographics and baseline characteristics</p></caption><graphic xlink:href="NEUROLOGY2015708594TT1"/></table-wrap></sec><sec id="s2-2"><title>Safety and tolerability.</title><p>The tolerability profile of nVNS was satisfactory and generally similar to that of sham treatment (<xref ref-type="table" rid="T2">table 2</xref>). Most AEs were mild or moderate and transient. The most commonly reported AEs were upper respiratory tract infections and gastrointestinal symptoms. During the randomized phase, 6 nVNS-treated participants reported 12 AEs that were related or possibly related to the device, whereas 5 controls reported 8 such AEs. No SAEs occurred during the randomized phase. During the open-label phase, 5 participants reported 8 AEs that were related or possibly related to the device. Two participants reported SAEs during the open-label phase (i.e., appendicitis and worsening headache); both were unrelated to the device. No discontinuations due to device-related AEs occurred.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Incidence of adverse events</p></caption><graphic xlink:href="NEUROLOGY2015708594TT2"/></table-wrap></sec><sec id="s2-3"><title>Number of headache days.</title><p>The mean number of headache days in the nVNS group (n = 30) was 20.8 (95% CI 18.9&#x02013;22.6) at baseline and 19.4 (95% CI 16.6&#x02013;22.1) at month 2 (end of the randomized phase), representing a mean change of &#x02212;1.4 (95% CI &#x02212;3.7 to 0.77; <italic>p</italic> = 0.44) (<xref ref-type="fig" rid="F2">figure 2A</xref>). The mean number of headache days in controls (n = 29) was 22.3 (95% CI 20.4&#x02013;24.1) at baseline and 22.0 (95% CI 19.5&#x02013;24.6) at month 2, demonstrating a mean change of &#x02212;0.2 (95% CI &#x02212;1.5 to 1.1; <italic>p</italic> = 0.72) (<xref ref-type="fig" rid="F2">figure 2A</xref>). The mean change from baseline was not statistically different between groups (<italic>p</italic> = 0.56). The difference between groups was slightly more pronounced in the <italic>PP population</italic>, with mean changes of &#x02212;2.0 (95% CI &#x02212;4.4 to 0.4) for nVNS and &#x02212;0.1 (95% CI &#x02212;1.6 to 1.4) for sham (<italic>p</italic> = 0.35).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Effects of noninvasive vagus nerve stimulation (nVNS) on the change in number of headache days per 28 days</title><p>(A) Mean change in headache days per 28 days from baseline through the open-label phase (<italic>intent-to-treat population</italic>). Imputation for missing data was performed using the last observation carried forward. <sup>a</sup>Received open-label nVNS after month 2. *<italic>p</italic> &#x0003c; 0.05 vs baseline. (B) Mean change in headache days per 28 days from baseline through the duration of nVNS treatment (<italic>per-protocol completer population</italic>). <sup>a</sup>The 2-, 4-, and 6-month completers were from the 59 participants initially randomized to either nVNS or sham treatment. <sup>b</sup>The 8-month completers were from the 30 participants initially randomized to nVNS treatment. <sup>c</sup>One participant who completed 8 months of nVNS initiated gabapentin treatment during the study and was therefore excluded from 8-month completer analyses. *<italic>p</italic> &#x0003c; 0.05 vs baseline. **<italic>p</italic> &#x0003c; 0.01 vs baseline.</p></caption><graphic xlink:href="NEUROLOGY2015708594FF2"/></fig><p>Persistent prophylactic nVNS use was associated with continued reductions in the number of headache days. After the open-label phase, participants initially assigned to nVNS had a mean of 17.2 (95% CI 13.8&#x02013;20.5) headache days and a mean change from baseline of &#x02212;3.6 (95% CI &#x02212;6.3 to &#x02212;0.87; <italic>p</italic> = 0.02) after 8 months of treatment (<xref ref-type="fig" rid="F2">figure 2A</xref>). Participants initially randomized to sham treatment had a mean of 19.7 (95% CI 16.5&#x02013;23.0) headache days and a mean change from baseline of &#x02212;2.5 (95% CI &#x02212;5.0 to &#x02212;0.04; <italic>p</italic> = 0.06) after 6 months of nVNS (<xref ref-type="fig" rid="F2">figure 2A</xref>). To investigate the effect of treatment persistence, mean changes in the number of headache days were analyzed without LOCF imputation. More pronounced and clinically meaningful reductions from baseline at months 4, 6, and 8 (&#x02212;3.7, &#x02212;6.1, and &#x02212;8.0 headache days, respectively) were observed in the nVNS group (month 4, <italic>p</italic> &#x0003c; 0.05; months 6 and 8, <italic>p</italic> &#x0003c; 0.01). The mean change of &#x02212;6.0 headache days for controls reached statistical significance at month 8 (<italic>p</italic> &#x0003c; 0.05).</p><p>In the <italic>PP completer population</italic>, longer duration was associated with greater reductions in headache days from study baseline (nVNS) and from month 2 (sham) (<xref ref-type="fig" rid="F2">figure 2B</xref>). These mean reductions were 1.6 (95% CI 0.1&#x02013;3.1; <italic>p</italic> = 0.06) for 2-month completers (n = 44), 3.9 (95% CI 1.4&#x02013;6.3; <italic>p</italic> = 0.004) for 4-month completers (n = 32), 6.2 (95% CI 3.2&#x02013;9.3; <italic>p</italic> &#x0003c; 0.0001) for 6-month completers (n = 26), and 7.9 (95% CI 11.9&#x02013;3.8; <italic>p</italic> = 0.0009) for 8-month completers (n = 15) (<xref ref-type="fig" rid="F2">figure 2B</xref>). In contrast with 2-month completers, 4-, 6-, and 8-month completers each experienced significant reductions at 2-, 4-, 6-, and 8-month timepoints except for the 8-month completers at the 2-month timepoint (<italic>p</italic> = 0.06) (<xref ref-type="fig" rid="F2">figure 2B</xref>).</p></sec><sec id="s2-4"><title>Treatment response.</title><p>At month 2, 10.0% (3/30) of participants from the nVNS group had a &#x02265;50% response, and 3.3% (1/30) experienced a &#x02265;75% response. No controls experienced a &#x02265;50% response. In the <italic>PP population</italic>, 11.5% (3/26) of participants from the nVNS group had a &#x02265;50% response; 3.8% (1/26) experienced a &#x02265;75% response. No controls experienced a &#x02265;50% response. In the <italic>PP completer populations</italic>, the proportion of participants who achieved a &#x02265;50% response increased with longer duration of treatment throughout the open-label phase (<xref ref-type="fig" rid="F3">figure 3</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Participants who achieved a &#x02265;50% treatment response with noninvasive vagus nerve stimulation (nVNS) (<italic>per-protocol completer population</italic>)</title><p><sup>a</sup>The 2-, 4-, and 6-month completers were from the 59 participants initially randomized to either nVNS or sham treatment. <sup>b</sup>The 8-month completers were from the 30 participants initially randomized to nVNS treatment. <sup>c</sup>One participant who completed 8 months of nVNS initiated gabapentin treatment during the study and was therefore excluded from 8-month completer analyses.</p></caption><graphic xlink:href="NEUROLOGY2015708594FF3"/></fig></sec><sec id="s2-5"><title>Acute medication use.</title><p>Rates of acute medication use were comparable between groups and remained stable from baseline (89.8%) through the open-label phase (81.5%).</p></sec><sec id="s2-6"><title>Treatment adherence, satisfaction, and ease of use.</title><p>Mean treatment adherence for both groups was &#x02265;95% during the randomized phase and &#x02265;92% during the open-label phase. At month 2, 58.3% (14/24) of nVNS-treated participants and 41.7% (10/24) of sham-treated participants were at least <italic>a little satisfied</italic> with treatment (<italic>p</italic> = 0.25; &#x003c7;<sup>2</sup> test). Among participants who completed the open-label phase, 88.5% (23/26) were satisfied with treatment. Most participants found the device <italic>somewhat easy</italic> or <italic>very easy</italic> to use (nVNS, 20/24; 83.3%; sham, 22/24; 91.7%).</p></sec><sec id="s2-7"><title>Blinding evaluation.</title><p>At the beginning of the randomized phase, a similar number of participants in each arm (nVNS, 37.9% [11/29]; sham, 39.3% [11/28]) correctly identified their treatment. The groups had similar Bang index values (nVNS, 0.31 [95% CI 0.15&#x02013;0.47]; sham, 0.32 [95% CI 0.15&#x02013;0.49]), each indicating that blinding was not achieved. At month 2, Bang index values of 0.04 (95% CI 0.0&#x02013;0.25) for nVNS and 0.54 (95% CI 0.31&#x02013;0.77) for sham suggest blinding was achieved in the nVNS group but not in controls.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>We demonstrated that nVNS for CM prevention was well-tolerated and identified no safety issues; preliminary efficacy results showed that the reduction in headache days during the 2-month randomized phase among participants receiving nVNS compared with controls was not significant. We assessed whether longer treatment duration was associated with clinically meaningful results, as previously reported in a study of neuromodulation in CM.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Participants originally randomized to nVNS and who continued open-label treatment for 6 months had a significant reduction from baseline in the number of headache days. Longer treatment durations were associated with greater reductions in number of headache days and higher &#x02265;50% response rates, recognizing that the 27 participants who completed the open-label phase of the trial and received longer treatment (16 and 11 of whom were initially randomized to nVNS and sham, respectively) may have been self-selected.</p><p>Among study completers, the &#x02265;50% response rate increased with time on treatment, which supports the slow accrual of clinical benefits over time reported in VNS studies of epilepsy and depression.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Loss to follow-up cannot explain this result; however, regression toward the mean may be a confounding factor. The association between longer nVNS treatment duration and a gradual reduction in headache days suggests that participants who discontinued the study might have benefited from continued treatment, consistent with other findings in the literature.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Conversely, participants who continued treatment may represent self-identified responders for whom the device is effective.</p><p>Study limitations included the small sample size, blinding challenges, and high discontinuation rate. Blinding in device studies is challenging, especially in comparison with drug studies.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Our sham device was identical to the nVNS device but did not deliver an active signal. A sham device should mimic the functionality and sensation of active treatment without producing treatment effects or device-related AEs. Missing data and high discontinuation rates occurring disproportionately across treatment groups can affect study outcomes. In this study, discontinuation rates were higher in controls than in the nVNS group; however, no discontinuations stemmed from device-related AEs.</p><p>The emergence of noninvasive neuromodulation devices has sparked interest in their application in migraine therapy. Two short-term, double-blind, randomized, controlled trials have examined prophylactic therapy for migraine using noninvasive neuromodulation devices.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> One multicenter sham-controlled study reported a significant reduction in the mean number of headache days following transcutaneous supraorbital stimulation for 3 months in participants with migraine; however, the proportion of participants with CM was unknown.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> A single-center controlled study of prophylactic transcutaneous auricular VNS therapy in CM showed that the reduction in number of headache days was significantly greater at a stimulation frequency of 1 Hz than at 25 Hz; however, no sham arm was available for comparison.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> EVENT is the first multicenter, double-blind, randomized, sham-controlled trial to demonstrate the long-term (8-month) tolerability and preliminarily evaluate the efficacy of prophylactic nVNS therapy in a clinically defined CM population. Stimulation parameters used in EVENT (i.e., 2-minute stimulations administered 3 times per day on the right side of the neck) were based on both previous open-label clinical studies in migraine and cluster headache<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> and preclinical models of migraine and airways disease,<sup><xref rid="R25" ref-type="bibr">25</xref><xref ref-type="bibr" rid="R26">&#x02013;</xref><xref rid="R27" ref-type="bibr">27</xref></sup> but bilateral stimulations are currently being used in ongoing studies, which may affect efficacy results observed in these and future trials. Findings from the animal migraine models suggest that nVNS may exert beneficial effects via the suppression of glutamate levels and cortical spreading depression, a key factor in migraine pathophysiology.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> Prophylactic nVNS has been shown to be clinically beneficial<sup><xref rid="R19" ref-type="bibr">19</xref></sup> and cost-effective<sup><xref rid="R28" ref-type="bibr">28</xref></sup> in chronic cluster headache. Findings from EVENT expand the evidence regarding the potential role of noninvasive neuromodulation in headache therapy. Given the need for novel prophylactic therapies for CM and the high cost of the currently approved medication,<sup><xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup> nVNS may serve as a well-tolerated and potentially cost-effective alternative for patients with CM.</p><p>nVNS is a highly feasible, well-tolerated, and convenient therapy. Although self-selection bias is associated with the long-term findings, the continued reduction in headache days over the 6-month open-label phase suggests that nVNS may offer a clinical benefit to patients with CM. Longer-term use of nVNS in treatment responders would be reflective of clinical practice.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> On the basis of the lack of a plateau in effects seen during the open-label phase, larger studies using modified stimulation parameters and longer open-label periods may validate the use of nVNS in migraine therapy; a study with a 9-month open-label period is currently planned.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_5_529__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000002918_Figure_e-1.pdf"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Coinvestigators</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_5_529_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_WNL.0000000000002918_Coinvestigator_Appendix.docx"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the investigators and study sites (coinvestigator appendix at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link>); the EVENT study investigators thank the nurses and study coordinators; professional writing and editorial support (i.e., technical editing, copyediting, preparation of tables and figures, and clerical assistance) for this manuscript was provided by MedLogix Communications, LLC (Schaumburg, IL) under the direction of the authors.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">This study was sponsored by electroCore, LLC. Professional writing and editorial support (i.e., technical editing, copyediting, preparation of tables and figures, and clerical assistance) from MedLogix Communications, LLC, funded by electroCore, LLC, was based on author direction throughout draft development and revisions. Data analysis support from NAMSA was funded by electroCore, LLC. Dr. Stephen D. Silberstein, Dr. Peter J. Goadsby, Eric J. Liebler, and Kristy A. Simmons contributed to the EVENT study design and provided detailed input into the development of the manuscript. Stefanie Dorlas is responsible for drafting/revising the manuscript for content, including medical writing for content. All primary investigators were involved in participant recruitment and treatment for the EVENT study. All authors participated in data collection, interpretation, and validation. Kristy A. Simmons, Eric J. Liebler, and NAMSA were involved in data analysis. All authors reviewed, critiqued, and contributed to revision of the manuscript content and provided approval of the final manuscript draft to be submitted to <italic>Neurology&#x000ae;</italic>. The corresponding author, Dr. Stephen D. Silberstein, had full access to all the study data and had final responsibility for the decision to submit the manuscript for publication.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study was sponsored by electroCore, LLC.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">S. Silberstein has received honoraria as a consultant and/or advisory panel member from Alder Biopharmaceuticals; Allergan, Inc.; Amgen Inc.; Avanir Pharmaceuticals, Inc.; Depomed, Inc.; Dr. Reddy's Laboratories Ltd.; electroCore, LLC; eNeura, Inc.; Ipsen Biopharmaceuticals; Medscape, LLC; Medtronic, Inc.; Mitsubishi Tanabe Pharma America, Inc.; NINDS; St. Jude Medical; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; and Trigemina, Inc. A. Calhoun has participated as an advisory board member for Allergan, Inc.; Depomed, Inc.; and Teva Pharmaceuticals. Dr. Calhoun has received honoraria from and participated as a speaker's bureau member for Depomed, Inc.; Merck &#x00026; Co., Inc.; and Teva Pharmaceuticals. She has also received research support from Autonomic Technologies, Inc.; electroCore, LLC; and Scion NeuroStim LLC. B. Grosberg reports no disclosures relevant to the manuscript. R. Lipton receives research support from the National Headache Foundation and the NIH: PO1AG003949 (program director), RO1AG025119 (investigator), RO1AG022374-06A2 (investigator), RO1AG034119 (investigator), and RO1AG12101 (investigator); serves on the editorial board of <italic>Neurology</italic> and as senior advisor to <italic>Headache</italic>; has reviewed for the National Institute on Aging and NINDS; holds stock options in eNeura, Inc.; and serves as a consultant or advisory board member or has received honoraria from Alder Biopharmaceuticals; Allergan, Inc.; American Headache Society; Amgen, Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Boston Scientific Corporation; CoLucid Pharmaceuticals, Inc.; Dr. Reddy's Laboratories Ltd.; electroCore, LLC; Eli Lilly and Company; eNeura Therapeutics; Informa; Merck &#x00026; Co., Inc.; Teva Pharmaceuticals; and Vedanta Biosciences. R. Cady has participated as a consultant, advisory board member, and speaker's bureau member for Allergan, Inc., Depomed, Inc., and Teva Pharmaceutical Industries Ltd. Dr. Cady has also participated as an advisory board member for Aerocrine Inc.; Amgen, Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Boston Scientific Corporation; Dr. Reddy's Laboratories Ltd.; electroCore, LLC; Novartis; and Suda Ltd. He has served as a consultant and speaker's bureau member for Impax Pharmaceuticals; as a consultant for Becker Pharmaceuticals Consulting and Zosano Pharma Corporation; and as a speaker's bureau member for Merck &#x00026; Co., Inc. Dr. Cady has also received research support from Alder Biopharmaceuticals; Allergan, Inc.; Amgen Inc.; AstraZeneca; Autonomic Technologies, Inc.; Boston Scientific Corporation; Capnia; Daiichi-Sankyo; Dr. Reddy's Laboratories Ltd.; electroCore, LLC; Eli Lilly and Company; Labrys Biologics, Inc.; OptiNose; Pharmalyte Solutions, LLC; Questcor Pharmaceuticals, Inc.; Tian Medical; and Vivid Pharmaceuticals. P. Goadsby has received honoraria from Ajinomoto Pharmaceuticals Co., Ltd.; Akita Pharmaceuticals, Ltd.; Amgen Inc.; Alder Biopharmaceuticals; Allergan, Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Cipla Ltd.; CoLucid Pharmaceuticals, Inc.; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; eNeura, Inc.; W.L. Gore &#x00026; Associates, Inc.; Heptares Therapeutics; Ethicon, Inc.; NEJM Journal Watch; NuPathe Inc.; Pfizer, Inc.; Promius Pharma, LLC; Teva Pharmaceutical Industries Ltd.; UptoDate&#x000ae;.com (outside the submitted work); Wells Fargo; and Zosano Pharma Corporation. He has also received honoraria for medicolegal work in headache and grants from Allergan, Inc., and Amgen Inc. and has a pending patent for magnetic stimulation for headache. K. Simmons was an employee of electroCore, LLC at the time of study completion. C. Mullin is an employee of NAMSA. E. Liebler is an employee of electroCore, LLC and receives stock ownership. Stefanie Dorlas is employed by MedLogix Communications, LLC, as a medical writer. J. Saper has received research grants from Achelios Therapeutics, Inc.; Alder Biopharmaceuticals; Allergan, Inc.; Amgen Inc.; Astellas Pharma Inc.; Autonomic Technologies, Inc.; Cerephex Corporation; Daiichi-Sankyo; Dr. Reddy's Laboratories Ltd.; GlaxoSmithKline; Labrys Biologics, Inc.; Lilly; Merck &#x00026; Co., Inc.; Pfizer, Inc.; Scion NeuroStim LLC; Vanda Pharmaceuticals; and Winston Laboratories, Inc.; and has received honoraria as a consultant for Alder Biopharmaceuticals; Allergan, Inc.; Johnson &#x00026; Johnson (Ethicon, Inc.); the Migraine Research Foundation; NuPathe Inc.; Purdue Pharma; Supernus Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; and Tian Pharmaceutical Co. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000002918">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G2">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G3">CM</term><def><p>chronic migraine</p></def></def-item><def-item><term id="G4">ITT</term><def><p>intent-to-treat</p></def></def-item><def-item><term id="G5">LOCF</term><def><p>last observation carried forward</p></def></def-item><def-item><term id="G6">nVNS</term><def><p>noninvasive vagus nerve stimulation</p></def></def-item><def-item><term id="G7">PP</term><def><p>per-protocol</p></def></def-item><def-item><term id="G8">SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term id="G9">VNS</term><def><p>vagus nerve stimulation</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><collab>Headache Classification Committee of the International Headache Society</collab>. <article-title>The International Classification of Headache Disorders, 3rd edition (beta version)</article-title>. <source>Cephalalgia</source>
<year>2013</year>;<volume>33</volume>:<fpage>629</fpage>&#x02013;<lpage>808</lpage>.<pub-id pub-id-type="pmid">23771276</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwedt</surname><given-names>TJ</given-names></name></person-group>
<article-title>Chronic migraine</article-title>. <source>BMJ</source>
<year>2014</year>;<volume>348</volume>:<fpage>g1416</fpage>.<pub-id pub-id-type="pmid">24662044</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Sprenger</surname><given-names>T</given-names></name></person-group>
<article-title>Current practice and future directions in the prevention and acute management of migraine</article-title>. <source>Lancet Neurol</source>
<year>2010</year>;<volume>9</volume>:<fpage>285</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">20170842</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aurora</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Dodick</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Turkel</surname><given-names>CC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial</article-title>. <source>Cephalalgia</source>
<year>2010</year>;<volume>30</volume>:<fpage>793</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">20647170</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Dodick</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Aurora</surname><given-names>SK</given-names></name>, <etal>et al.</etal></person-group>
<article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial</article-title>. <source>Cephalalgia</source>
<year>2010</year>;<volume>30</volume>:<fpage>804</fpage>&#x02013;<lpage>814</lpage>.<pub-id pub-id-type="pmid">20647171</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>JV</given-names></name></person-group>
<article-title>Left vagal nerve stimulation in children with medically refractory epilepsy: The Pediatric VNS Study Group</article-title>. <source>J Pediatr</source>
<year>1999</year>;<volume>134</volume>:<fpage>563</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">10228290</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaronson</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Carpenter</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Conway</surname><given-names>CR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects</article-title>. <source>Brain Stimul</source>
<year>2013</year>;<volume>6</volume>:<fpage>631</fpage>&#x02013;<lpage>640</lpage>.<pub-id pub-id-type="pmid">23122916</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenaerts</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Oommen</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Skaggs</surname><given-names>V</given-names></name></person-group>
<article-title>Can vagus nerve stimulation help migraine?</article-title>
<source>Cephalalgia</source>
<year>2008</year>;<volume>28</volume>:<fpage>392</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">18279429</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauskop</surname><given-names>A</given-names></name></person-group>
<article-title>Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches</article-title>. <source>Cephalalgia</source>
<year>2005</year>;<volume>25</volume>:<fpage>82</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">15658944</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecchini</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Mea</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tullo</surname><given-names>V</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data</article-title>. <source>Neurol Sci</source>
<year>2009</year>;<volume>30</volume>(<issue>suppl 1</issue>):<fpage>S101</fpage>&#x02013;<lpage>S104</lpage>.<pub-id pub-id-type="pmid">19415436</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hord</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Mueed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Adamolekun</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Naritoku</surname><given-names>DK</given-names></name></person-group>
<article-title>The effect of vagus nerve stimulation on migraines</article-title>. <source>J Pain</source>
<year>2003</year>;<volume>4</volume>:<fpage>530</fpage>&#x02013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">14636821</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadler</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Purdy</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Rahey</surname><given-names>S</given-names></name></person-group>
<article-title>Vagal nerve stimulation aborts migraine in patient with intractable epilepsy</article-title>. <source>Cephalalgia</source>
<year>2002</year>;<volume>22</volume>:<fpage>482</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">12133049</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Da Silva</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Calhoun</surname><given-names>AH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Non-invasive vagus nerve stimulation for chronic migraine prevention in a prospective, randomized, sham-controlled pilot study (the EVENT study): report from the double-blind phase</article-title>. <source>Headache</source>
<year>2014</year>;<volume>54</volume>:<fpage>LBP19</fpage>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><collab>Headache Classification Subcommittee of the International Headache Society</collab>. <article-title>The International Classification of Headache Disorders: 2nd edition</article-title>. <source>Cephalalgia</source>
<year>2004</year>;<volume>24</volume>(<issue>suppl 1</issue>):<fpage>9</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">14979299</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olesen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bousser</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>New appendix criteria open for a broader concept of chronic migraine</article-title>. <source>Cephalalgia</source>
<year>2006</year>;<volume>26</volume>:<fpage>742</fpage>&#x02013;<lpage>746</lpage>.<pub-id pub-id-type="pmid">16686915</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Flaherty</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Kolahi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J</given-names></name></person-group>
<article-title>Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol</article-title>. <source>Clin Res Reg Aff</source>
<year>2010</year>;<volume>27</volume>:<fpage>42</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Dodick</surname><given-names>DW</given-names></name></person-group>
<article-title>Operational diagnostic criteria for chronic migraine: expert opinion</article-title>. <source>Headache</source>
<year>2014</year>;<volume>54</volume>:<fpage>1258</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">24990187</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodick</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>KL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study</article-title>. <source>Cephalalgia</source>
<year>2015</year>;<volume>35</volume>:<fpage>344</fpage>&#x02013;<lpage>358</lpage>.<pub-id pub-id-type="pmid">25078718</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaul</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Silver</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Non-invasive vagus nerve stimulation for prevention and acute treatment of chronic cluster headache (PREVA): a randomized controlled study</article-title>. <source>Cephalalgia</source>
<year>2016</year>;<volume>36</volume>:<fpage>534</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">26391457</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadbent</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>van den Eynde</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Guillaume</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Blinding success of rTMS applied to the dorsolateral prefrontal cortex in randomised sham-controlled trials: a systematic review</article-title>. <source>World J Biol Psychiatry</source>
<year>2011</year>;<volume>12</volume>:<fpage>240</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">21426265</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoenen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vandersmissen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jeangette</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>80</volume>:<fpage>697</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">23390177</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straube</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ellrich</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Eren</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Blum</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ruscheweyh</surname><given-names>R</given-names></name></person-group>
<article-title>Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial</article-title>. <source>J Headache Pain</source>
<year>2015</year>;<volume>16</volume>:<fpage>543</fpage>.<pub-id pub-id-type="pmid">26156114</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Grosberg</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Mauskop</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cady</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>KA</given-names></name></person-group>
<article-title>Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study</article-title>. <source>Cephalalgia</source>
<year>2014</year>;<volume>34</volume>:<fpage>986</fpage>&#x02013;<lpage>993</lpage>.<pub-id pub-id-type="pmid">24607501</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesbitt</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Marin</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Tompkins</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ruttledge</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>
<article-title>Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment</article-title>. <source>Neurology</source>
<year>2015</year>;<volume>84</volume>:<fpage>1249</fpage>&#x02013;<lpage>1253</lpage>.<pub-id pub-id-type="pmid">25713002</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Ay</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lopes de Morais</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Vagus nerve stimulation inhibits cortical spreading depression</article-title>. <source>Pain</source>
<year>2016</year>;<volume>157</volume>:<fpage>797</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">26645547</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Emala</surname><given-names>CW</given-names></name></person-group>
<article-title>Low voltage vagal nerve stimulation reduces bronchoconstriction in guinea pigs through catecholamine release</article-title>. <source>Neuromodulation</source>
<year>2012</year>;<volume>15</volume>:<fpage>527</fpage>&#x02013;<lpage>536</lpage>.<pub-id pub-id-type="pmid">22551486</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshinsky</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Hekierski</surname><given-names>H</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Cooper</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>BJ</given-names></name></person-group>
<article-title>Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia</article-title>. <source>Pain</source>
<year>2014</year>;<volume>155</volume>:<fpage>1037</fpage>&#x02013;<lpage>1042</lpage>.<pub-id pub-id-type="pmid">24530613</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaul</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Straube</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reuter</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name></person-group>
<article-title>Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache in Germany</article-title>. <source>Cephalalgia</source>
<year>2015</year>;<volume>35</volume>:<fpage>81</fpage>.</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><article-title>Botulinum toxin for chronic migraine</article-title>. <source>Med Lett Drugs Ther</source>
<year>2011</year>;<volume>53</volume>:<fpage>7</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21252842</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zafar</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Quarshie</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>F</given-names></name></person-group>
<article-title>Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine: real-life data in 254 patients from Hull, U.K</article-title>. <source>J Headache Pain</source>
<year>2014</year>;<volume>15</volume>:<fpage>54</fpage>.<pub-id pub-id-type="pmid">25178393</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moscato</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Moscato</surname><given-names>FR</given-names></name></person-group>
<article-title>A survey of patient perceptions of non-invasive vagus nerve stimulation (nVNS) therapy for acute migraine attacks</article-title>. <source>Cephalalgia</source>
<year>2015</year>;<volume>35</volume>(<issue>suppl 6</issue>):<fpage>PO016</fpage>. Abstract.</mixed-citation></ref></ref-list></back></article>